Abstract
Deep brain stimulation is a viable and efficacious treatment option for dystonia. While the internal pallidum serves as the primary target, more recently, stimulation of the subthalamic nucleus (STN) has been investigated. However, optimal targeting within this structure and its complex surroundings have not been studied in depth. Indeed, multiple historical targets that have been used for surgical treatment of dystonia are directly adjacent to the STN. Further, multiple types of dystonia exist, and outcomes are variable, suggesting that not all types would profit maximally from the exact same target. Therefore, a thorough investigation of the neural substrates underlying effects on dystonia symptoms is warranted.
Here, we analyze a multi-center cohort of isolated dystonia patients with subthalamic implantations (N = 58) and relate their stimulation sites to improvement of appendicular and cervical symptoms as well as blepharospasm. Stimulation of the ventral oral posterior nucleus of thalamus and surrounding regions was associated with improvement in cervical dystonia, while stimulation of the dorsolateral STN was associated with improvement in limb dystonia and blepharospasm. This dissociation was also evident for structural connectivity, where the cerebellothalamic, corticospinal and pallidosubthalamic tracts were associated with improvement of cervical dystonia, while hyperdirect and subthalamopallidal pathways were associated with alleviation of limb dystonia and blepharospasm. Importantly, a single well-placed electrode may reach the three optimal target sites. On the level of functional networks, improvement of limb dystonia was correlated with connectivity to the corresponding somatotopic regions in primary motor cortex, while alleviation of cervical dystonia was correlated with connectivity to the recently described ‘action-mode’ network that involves supplementary motor and premotor cortex. Our findings suggest that different types of dystonia symptoms are modulated via distinct networks. Namely, appendicular dystonia and blepharospasm are improved with modulation of the basal ganglia, and, in particular, the subthalamic circuitry, including projections from the primary motor cortex. In contrast, cervical dystonia was more responsive when engaging the cerebello-thalamo-cortical circuit, including direct stimulation of ventral thalamic nuclei.
These findings may inform DBS targeting and image-based programming strategies for patient-specific treatment of dystonia.
Competing Interest Statement
R.L. reports personal fees from Medtronic. M.D.F. has intellectual property on the use of brain connectivity imaging to analyze lesions and guide brain stimulation, is a consultant for Magnus Medical, Soterix, Abbott, and Boston Scientific, and has received research funding from Neuronetics. A.H. reports lecture fees for Boston Scientific and is a consultant for FxNeuromodulation and Abbott. K.B., C.N., T.A.D., B.H., G.M.M., N.L., S.O., B.H.B., B.A.F., E.M.G., N.U.F.D., C.G., M.H., P.A.S., J.L.O., Y.W., and C.Z. declare no competing interests.
Funding Statement
B.H. is supported by Einstein Center for Neurosciences Berlin. B.H.B. is supported by the Prof. Dr. Klaus Thiemann Foundation (Parkinson Fellowship 2022). R.L. is supported by BIH Charite Clinician Scientist Program. M.H. is supported by the NINDS Intramural Program. C.G. received honoraria from the Movement Disorder Society for educational activities and academic research support from the Volkswagen Stiftung (Freigeist Fellowship). M.D.F. is supported by grants from the NIH (R01MH113929, R21MH126271, R56AG069086, R21NS123813, R01NS127892, R01MH130666, UM1NS132358), Neuronetics, the Kaye Family Research Endowment, the Ellison / Baszucki Family Foundation, and the Manley Family. A.H. is supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, 424778381 - TRR 295), Deutsches Zentrum fur Luft- und Raumfahrt (DynaSti grant within the EU Joint Programme Neurodegenerative Disease Research, JPND), the National Institutes of Health (R01 13478451, 1R01NS127892-01, 2R01 MH113929 & UM1NS132358) as well as the New Venture Fund (FFOR Seed Grant).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The collection and analysis of all patient data was approved by the Institutional Review Board of Brigham & Women's Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The code necessary to reproduce the findings of the study is available at https://github.com/Kinway25/leaddbs/tree/STN_DBS_DYT. Upon acceptance, the data necessary to reproduce the findings will be deposited in a separate repository following requirements of the publisher. The raw data are not publicly available due to patient privacy restrictions, but can be requested from the authors within the scope of a data sharing agreement.
